Recombinant virus-like particle COVID-19 vaccine (Medicago)

重组病毒样颗粒新型冠状病毒疫苗(Medicago)

Report date: 2022/03/08 09:32:26

Base Information

Drug NameRecombinant virus-like particle COVID-19 vaccine (Medicago)
Drug Alias NameCoronavirus-like particle COVID-19 vaccine (Medicago)CoVLPVIRUS-LIKE PARTICLES (VLP) OF SARS-COV-2 SPIKE PROTEINCOVID-19 Vaccine (plant-based virus-like particles [VLP], recombinant, adjuvanted)COVIFENZ +[6] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date2022/02/24
Country/TerritoryCanadaUnited StatesMexico +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMedicago Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcMedicago Inc
Inactive CompaniesMitsubishi Tanabe Pharma Corp
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank